Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER-WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape: https://bit.ly/3XGT53f #pivotaltrial #clinicalresearch #cloverwam #waldenstrommacrocglobulinemia #iopofosine #marketlandscape #KOLEvent
Cellectar Biosciences, Inc.
Biotechnology
Florham Park, New Jersey 3,115 followers
Learn more about the Waldenstrom's Macroglobulinemia pivotal clinical study at www.wmclinicaltrial.com.
About us
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The company is currently enrolling in a global, pivotal Phase 2 Part B (CLOVER-WaM) expansion study in Waldenstrom’s macroglobulinemia (WM) patients who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The WM study will enroll up to 50 patients to evaluate the efficacy and safety of CLR 131 for marketing approval. For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Facebook and YouTube.
- Website
-
https://www.cellectar.com
External link for Cellectar Biosciences, Inc.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Florham Park, New Jersey
- Type
- Public Company
- Specialties
- PDC Cancer Therapeutics and Diagnostics, Targeted Delivery of Oncologic Payloads, Early-Stage Chemotherapeutic Drug Conjugates, and Hematologic Malignancies
Locations
-
Primary
100 Campus Dr
207
Florham Park, New Jersey 07932, US
-
Employees at Cellectar Biosciences, Inc.
-
Matt Hagan
Vice President, Radiotherapy Alliances and Operations
-
Brenda Wolling
Executive Director Regulatory Affairs with Cellectar BioSciences
-
Douglas Swirsky
Chief Financial Officer at MaxCyte, Inc.
-
Stefan Loren, Ph.D.
Managing Director Healthcare Investment Banking at Oppenheimer
Updates
-
Our Chief Operations Officer Jarrod Longcor is participating in a panel at #SNMMI2024 and will be able to share Cellectar's journey, including information about iopofosine131. We are so proud to be a part of this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Annual Meeting and to have Jarrod speak!
As the premier radiotherapeutics, nuclear medicine and imaging conference, it is a real privilege to be able to participate in one of the panels and to share #Cellectar's and #iopofosine I 131's story at #SNMMI.
-
We are excited to attend the 2024 SNMMI meeting in Toronto. come learn more about Cellectar Biosciences at booth #1700! #SNMMIAnnualMeeting #SNMMI2024 #Toronto #NuclearMedicine #Radiotherapeutics Society of Nuclear Medicine and Molecular Imaging (SNMMI)
-
Cellectar Biosciences and City of Hope Cancer Center (City of Hope) Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides https://bit.ly/3WZY3Yo #MycosisFungoides #Collaboration #Biopharma
-
As we head into the long Memorial Day weekend, we honor the brave men and women who made the ultimate sacrifice defending our nation and our freedoms. Take a moment to reflect on their service and remember those who gave their lives for our country. We wish everyone a safe, fun, and meaningful Memorial Day. #MemorialDay #HonorThem #FreedomIsntFree #MemorialDayWeekend #Veterans
-
Cellectar Biosciences released its Q1 2024 financial results and corporate update this morning. See the associated presentation and listen to the audio of this morning’s call here: https://lnkd.in/gKiR5XwQ #FinancialResults #Biopharma #Oncology #Q12024 #radiopharmaceuticals #RPTs #Iopofosine
-
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update https://bit.ly/3V9MUDn #FinancialResults #Biopharma #Oncology #Q12024
-
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day https://bit.ly/3JPP2tt #radiopharmaceuticals #GuggenheimHealthcareTalks2024 #RPTs #Iopofosine #CLR131
-
Cellectar is so proud of you Kate! #PatientsEU2024 #Waldenstroms #clinicaltrials
Looking forward to sharing the CLOVER-WaM experience with Erica Mercado #PatientsEU2024 #Waldenstroms #clinicaltrials
-
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 https://bit.ly/3JRVekq #ConferenceCall #Waldenstroms #Biopharma #OncologyResearch